外科肿瘤学中的肠道微生物组:机制、围术期结局与治疗机会
本叙述性综述评估肠道微生物组在外科肿瘤学中的机制作用、作为风险分层生物标志物的潜力及治疗靶点价值。围术期干预可诱导与吻合口漏和肺炎相关的急性微生物变化,靶向调节(如合生元、术前口腔护理、幽门螺杆菌根除)可减少并发症,但黑色素瘤中抗生素暴露损害免疫检查点抑制剂疗效,粪菌移植可逆转耐药。
要点
- 围术期合生元可减少结直肠手术感染并发症达45%, major肝手术达64%。
- 术前口腔护理降低食管切除术后肺炎达50%,幽门螺杆菌根除使异时性胃癌风险减半。
- 黑色素瘤中预处理抗生素暴露损害免疫检查点抑制剂疗效,粪菌移植可逆转耐药达80%应答率。
核心结论
- 微生物组是短期手术恢复和长期肿瘤生存的关键可调节决定因素。
- 未来外科肿瘤实践需整合精准外科微生物介导的生物治疗以优化多学科癌症护理结局。
研究设计与样本
- 叙述性综述,综合当前文献评估微生物组对上下消化道(包括肠-肺轴)、肝胆胰系统及腹外恶性肿瘤(乳腺癌和黑色素瘤)的影响。
主要发现
- 失调微生物特征(癌微生物组)主动驱动肿瘤进展和免疫逃逸。
- 围术期干预诱导急性微生物变化,与吻合口漏和肺炎等严重并发症相关。
- 围术期合生元减少结直肠手术感染并发症达45%, major肝手术达64%。
- 术前口腔护理降低食管切除术后肺炎达50%,幽门螺杆菌根除使异时性胃癌风险减半。
- 黑色素瘤中预处理抗生素暴露严重损害免疫检查点抑制剂疗效,粪菌移植可逆转免疫治疗耐药,试验中应答率达80%。
临床怎么用
- 考虑围术期使用合生元以减少结直肠和 major肝手术感染并发症。
- 术前口腔护理可降低食管切除术后肺炎风险。
- 幽门螺杆菌根除可降低异时性胃癌风险。
- 黑色素瘤患者预处理抗生素暴露可能损害免疫检查点抑制剂疗效,需谨慎评估。
- 粪菌移植可能作为逆转免疫治疗耐药的策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The gut microbiome is a fundamental determinant of gastrointestinal physiology. It is essential in maintaining host homeostasis while also implicated in cancer pathogenesis and alteration in physiological response to surgical stress. The aim of this narrative review was to evaluate the microbiome's mechanistic role in surgical oncology, assessing it as a biomarker for risk stratification and an emerging therapeutic target. METHODS: The current literature was synthesized to examine microbial impacts on tumorigenesis and perioperative surgical outcomes across the lower and upper gastrointestinal tracts (including the gut-lung axis), the hepatopancreatobiliary system, and extra-abdominal malignancies (breast cancer and melanoma). RESULTS: Dysbiotic microbial signatures, termed the oncobiome, actively drive tumour progression and immune evasion. Perioperative interventions induce acute microbial shifts linked to serious complications such as anastomotic leaks and pneumonia. Clinically, targeted modulation yields significant benefits, as demonstrated by perioperative synbiotics reducing infectious complications by up to 45% in colorectal surgery and 64% in major liver surgery. Furthermore, preoperative oral care reduces post-oesophagectomy pneumonia by up to 50%, while Helicobacter pylori eradication halves metachronous gastric cancer risk. However, a detrimental 'antibiotic paradox' exists in melanoma, where pretreatment antibiotic exposure severely impairs immune checkpoint inhibitor efficacy. Conversely, faecal microbiota transplantation can reverse this immunotherapy resistance, achieving up to 80% response rates in trials. CONCLUSION: The microbiome is a critical, modifiable determinant of both short-term surgical recovery and long-term oncological survival. Future surgical oncology practice will need to integrate precision surgical microbiome-mediated biotherapeutics to optimize outcomes in multidisciplinary cancer care.
引用
- Dang J, Lee Y, Wills MV, et al. Gut microbiome in surgical oncology: mechanisms, perioperative outcomes, and therapeutic opportunities. Br J Surg. 2026. PMID: 42370841. doi:10.1093/bjs/znag082
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。